Omeros reported $442.16M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Adma Biologics USD 203.84M 567K Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Cytokinetics USD 1.27B 18.17M Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Immunic USD 0 0 Jun/2024
Insmed USD 544.86M 180.93M Sep/2026
Knight Therapeutics CAD 77.91M 28.33M Dec/2025
MacroGenics USD 35.09M 1.42M Jun/2026
Omeros USD 442.16M 199K Sep/2023
Pacira USD 293.59M 69.53M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026